Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Expands By 65.4%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a significant growth in short interest in February. As of February 15th, there was short interest totalling 21,000 shares, a growth of 65.4% from the January 31st total of 12,700 shares. Based on an average trading volume of 74,300 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several hedge funds have recently added to or reduced their stakes in GNOM. SBI Securities Co. Ltd. bought a new position in shares of Global X Genomics & Biotechnology ETF during the fourth quarter valued at about $50,000. Oxinas Partners Wealth Management LLC purchased a new stake in Global X Genomics & Biotechnology ETF during the 4th quarter valued at about $103,000. Sanctuary Advisors LLC purchased a new stake in Global X Genomics & Biotechnology ETF during the 4th quarter valued at about $104,000. Sei Investments Co. bought a new position in Global X Genomics & Biotechnology ETF during the 4th quarter worth approximately $114,000. Finally, Smartleaf Asset Management LLC lifted its position in Global X Genomics & Biotechnology ETF by 11.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 12,604 shares of the company’s stock valued at $122,000 after purchasing an additional 1,265 shares during the last quarter. 56.95% of the stock is owned by institutional investors.

Global X Genomics & Biotechnology ETF Trading Down 0.9 %

Shares of GNOM traded down $0.08 during mid-day trading on Tuesday, reaching $8.80. The company’s stock had a trading volume of 49,141 shares, compared to its average volume of 68,029. Global X Genomics & Biotechnology ETF has a 52 week low of $8.64 and a 52 week high of $12.20. The stock has a market cap of $61.34 million, a PE ratio of -3.76 and a beta of 1.03. The company’s fifty day moving average price is $9.86 and its two-hundred day moving average price is $10.47.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.